For evaluatingthe potential of ApoE-rHDL as a nanoplatform for tumour-targeting siRNA delivery,activating transcription factor-5 (ATF5), an overexpressed anti-apoptotic transcriptionfactor in glioblastoma17, 18, was chosen as the target. This evidence concerns the gene ATF5 and neoplasm.